Lung infections in the HIV-infected adult

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 3, 2012, Pages

  Raju, Raghu ^a   Peters, Barry S ^b   Breen, Ronan A M ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

HIV; lung; Pneumocystis; pneumonia; tuberculosis

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

BACTERIAL PNEUMONIA; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VACCINATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; POINT OF CARE TESTING; REVIEW; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS; VACCINATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COINFECTION; HIV INFECTIONS; HUMANS; INCIDENCE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG DISEASES; PNEUMONIA, PNEUMOCYSTIS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; TUBERCULOSIS;

EID: 84859216272     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835213d3     Document Type: Review

References (96)

1. Pneumocystis pneumonia: Los Angeles. Centers for Disease Control (CDC). Morb Mortal Wkly Rep 1981; 30:250-252.
2. Buchacz K, Baker RK, Moorman AC, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008; 22:1345-1354.
3. Buchacz K, Baker RK, Palella FJ Jr, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24:1549-1559. Important review of the impact of ART on opportunistic infections in the US.
4. Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin Infect Dis 2011; 52:219-227. Excellent review of the evidence of the impact of HIV on influenza infection.
5. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007; 56:1-54.
6. Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006; 6:138.
7. Anema A, Mills E, Montaner J, et al. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 2008; 9:57-61.
8. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:430-433. (Pubitemid 29444433)
9. Madhi SA, Maskew M, Koen A, et al. Trivalent in activated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128-137. Important trial from South Africa of influenza vaccination in HIV-infected adults.
10. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of amonovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-146. Important study of immune responses to influenza vaccination in HIV infection.
11. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1- infected patients. Clin Infect Dis 2011; 52:122-127. Important study of immune responses to influenza vaccination in HIV infection.
12. Garcia-Leoni ME, Moreno S, Rodeno P, et al. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus. Arch Intern Med 1992; 152:1808-1812.
13. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary complications of HIV Infection Study Group. N Engl J Med 1995; 333:845-851.
14. Selwyn PA, Feingold AR, Hartel D, et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988; 2:267-272.
15. Yin Z, Rice BD, Waight P, et al. Invasive pneumococcal disease among HIVpositive individuals, 2000-2009. AIDS 2012; 26:87-94. Excellent epidemiological study of pneumococcal disease and HIV in the UK.
16. Siemieniuk RA, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis 2011; 11:314. Good Canadian analysis of pneumococcal infection in an HIV-infected population.
17. US Public Health Service (USPHS), Infectious Diseases Society of America (IDSA), USPHS/IDSA Prevention of opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials 2001; 2:493-554.
18. WHO. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008; 83:373-384.
19. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-1348. (Pubitemid 37186212)
20. Miiro G, Kayhty H, Watera C, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005; 192:1801-1805. (Pubitemid 41587832)
21. Gordon SB, Kayhty H, Molyneux ME, et al. Pneumococcal conjugate vaccine isimmunogenic in lung fluid of HIV-infected and immunocompetent adults. J Allergy Clin Immunol 2007; 120:208-210. (Pubitemid 46990497)
22. French N, Gordon SB, Mwalukomo T, et al. A trial of a7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-822. Good study from Africa of efficacy of pneumomococcal vaccination.
23. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Euro SIDA Study Group. Lancet 1999; 353:1293-1298. (Pubitemid 29178778)
24. Mocroft A, Reiss P, Kirk O, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4cell count <200 cells/microL? Clin Infect Dis 2010; 51:611-619. Very important study from a large European cohort of discontinuing PCP prophylaxis if stable on ART but CD4 cell count below 200 cells/ml.
25. Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/mL and virologic suppression: a systematic review. PLoS One 2011; 6:e28570. Clinically relevant review of PCP prophylaxis discontinuation when stable on ART but low CD4 cell count.
26. Harris JR, Marston BJ, Sangrujee N, et al. Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP). PLoS One 2011; 6:e23158. Very interesting analysis of PCP diagnostic strategies with respect to cost.
27. Morris AM, Masur H. A serologic test to diagnose pneumocystis pneumonia: are we there yet? Clin Infect Dis 2011; 53:203-204. Informative editorial on current PCP diagnostics.
28. Sax PE, Komarow L, Finkelman MA, et al. Blood (1->3)-beta-D-glucan as adiagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011; 53:197-202. Prospective evaluation in a large cohort of a blood test to diagnose PCP.
29. Helweg-Larsen J, Benfield T, Atzori C. Miller RF Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother 2009; 64:1282-1290.
30. Fei MW, Kim EJ, Sant CA, et al. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax 2009; 64:1070-1076.
31. Armstrong-James D, Copas AJ, Walzer PD, et al. A prognostic scoring tool for identification of patients at high and low risk of death from HIV-associated Pneumocystis jirovecii pneumonia. Int J STD AIDS 2011; 22:628-634. Interesting retrospective study attempting to establish a tool for prediction of PCP mortality using simple clinical variables.
32. Guidelines for intensified tuberculosis case-finding and isonaizid preventive therapy for people living with HIV in resource constrained settings. http:// www.who.int/hiv/pub/tb/9789241500708/en/index.html.
33. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010; 362:707-716. Important study of use a simple algorithm to screen for TB in HIV.
34. Getahun H, Kittikraisak W, Heilig CM, et al. Development of astandardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLOS Med 2011; 8:e1000391. Interesting work on use of a simple screening tool for TB in the setting of HIV.
35. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823-829. Important study of screening pre-ART.
36. Lawn SD, Kranzer K, Edwards DJ, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24:1323-1328. Good study of pre-ART screening for TB and impact upon TB-IRIS.
37. Dawson R, Masuka P, Edwards DJ, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis 2010; 14:52-58. A study reiterating the difficulties with simple chest radiographs in TB/HIV.
38. Holtz TH, KaberaG, Mthiyane T, et al. Use of aWHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smearnegative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 2011; 11:533-540. Interesting study of the clinical impact of a simple algorithm to guide treatment decisions in acutely unwell patients with suspected TB/HIV.
39. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015. Key study of Xpert MTB/RIF probe use in practice.
40. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-1505. Important early study of Xpert MTB/RIF probe use in practice.
41. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067. Important early field study of the Xpert MTB/Rif probe in TB/HIV.
42. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2011. [Epub ahead of print] Interesting work looking at the utility of lipoarabinomannan in TB diagnosis.
43. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492-1501. Key study of timing of ART initiation after starting antituberculosis therapy.
44. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-1481. Key study of timing of ART initiation after starting antituberculosis therapy.
45. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482-1491. Key study of timing of ART initiation after starting antituberculosis therapy.
46. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492-1501. [43]
47. Armstrong-James D, Copas AJ,Walzer PD, et al. A prognostic scoring tool for identification of patients at high and low risk of death from HIV-associated Pneumocystis jirovecii pneumonia. Int J STD AIDS 2011; 22:628-634. [31]
48. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823-829. [35]
49. Bhattacharya S, Niyogi SK, Bhattacharyya S, Fitzwater S, et al. High Rates of colonization with Drug Resistant Hemophilus Influenzae Type B and Streptococccus Pneumoniae in Unvaccinated HIV Infected Children from West Bengal. Indian J Pediatr 2011; 78:423-429.
50. Bickel M, von Hentig N,Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52:122-127. [11]
51. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-1481. [44]
52. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015. [39]
53. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-1505. [40]
54. Buchacz K, Baker RK, Palella Jr FJ, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24:1549-1559. [03]
55. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010; 362:707-716. [33]
56. Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect 2011; 17:25-33.
57. Coquet I, Pavie J, Palmer P, Barbier F, et al. Survival trends incritically ill HIV-infected patients in the highly active antiretroviral therapy era - art. no. R107. Crit Care 2010; 14:R107.
58. Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/mL and virologic suppression: a systematic review. PLoS One 2011; 6:e28570. [25]
59. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of amonovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-146. [10]
60. d'Ettorre G, Paiardini M, Ceccarelli G, Silvestri G, et al. HIV-Associated Immune Activation: From Bench to Bedside. Aids Res Hum Retrovir 2011; 27:355-364.
61. Dawson R, Masuka P, Edwards DJ, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis 2010; 14:52-58. [37]
62. French N, Gordon SB, Mwalukomo T, et al. A trial of a7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-822. [22]
63. Getahun H, Kittikraisak W, Heilig CM, et al. Development of astandardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLOS Med 2011; 8:e1000391. [34]
64. Harris JR, Marston BJ, Sangrujee N, et al. Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP). PLoS One 2011; 6:e23158. [26]
65. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482-1491. [45]
66. Holtz TH, Kabera G, Mthiyane T, et al. Use of aWHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 2011; 11:533-540. [38]
67. Holtz TH, Kabera G, Mthiyane T, Zingoni T, et al. Use of aWHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 2011; 11:533-540.
68. Katsidzira L, Fana GT, Makunike-Mutasa R, Ferrand RA. Pneumomediastinum in an HIV-infected patient with cytomegalovirus pneumonitis. Int J STD AIDS 2011; 22:179-180.
69. Langer F, Kreipe HH. Immunodeficiency and immunocompromised patients. Opportunistic infection of the lungs. Pathologe 2011; 32:411-417.
70. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067. [41]
71. Lawn SD, Fraenzel A, Kranzer K, Caldwell J, et al. Provider-initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral treatment. SAMJ S Afr Med J 2011; 101:258-262.
72. Lawn SD, Kerkhoff AD,Vogt M,Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2011. [Epub ahead of print] [42]
73. Lawn SD, Kranzer K, Edwards DJ, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24:1323-1328. [36]
74. Lawn SD, Torok ME, Wood R. Optimum time tostart antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011; 24:34-42.
75. Li HJ, Cheng JL. Imaging and pathological findings of AIDS complicated by pulmonary Rhodococcus equi infection. Chin Med J 2011; 124:968-972.
76. Madhi SA, Maskew M, Koen A, et al. Trivalent in activated influenza vaccine in African adults infected with humanimmunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128-137. [09]
77. Maro I, Lahey T, MacKenzie T, Mtei L, et al. Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania. Int J Tuberc Lung Dis 2010; 14:1447-1453.
78. Mermis J, Gu HH, Xue B, Li F, et al. Hypoxia-inducible factor- 1alpha/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling - art. no. 103. Respir Res 2011; 12:5.
79. Mocroft A, Reiss P, Kirk O, et al. Is itsafe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis 2010; 51:611-619. [24]
80. Mor SM, Aminawung JA, Demaria A, Naumova EN. Pneumonia and influenza hospitalization in HIV-positive seniors. Epidemiol Infect 2011; 139:1317-1325.
81. Morris AM, Masur H. A serologic test to diagnose pneumocystis pneumonia: are we there yet? Clin Infect Dis 2011; 53:203-204. [27]
82. Preidis GA, McCollum ED, Mwansambo C, Kazembe PN, et al. Pneumonia and Malnutrition are Highly Predictive of Mortality among African Children Hospitalized with Human Immunodeficiency Virus Infection or Exposure in the Era of Antiretroviral Therapy. J Pediatr 2011; 159:484-489.
83. Punpanich W, Groome M, Muhe L, Qazi SA, et al. Systematic Review on the Etiology and Antibiotic Treatment of Pneumonia in Human Immunodeficiency Virus-infected Children. Pediatr Infect Dis J 2011; 30:E192-E202.
84. Sathekge M, Maes A, Kgomo M, Stoltz A, et al. Use of F-18- FDG PET to Predict Response to First-Line Tuberculostatics in HIV-Associated Tuberculosis. J Nucl Med 2011; 52:880-885.
85. Sax PE, Komarow L, Finkelman MA, et al. Blood (1->3)-beta- D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011; 53:197-202. [28]
86. Schubel K, Bassinet L, Monnet I, Jabot L, et al. Pleurisy and pneumonia due to Mycobacterium chelonae. Rev Mal Respir 2011; 28:348-351.
87. Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin Infect Dis 2011; 52:219-227. [04]
88. Siemieniuk RA, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis 2011; 11:314. [16]
89. Steenhoff AP, Josephs JS, Rutstein RM, Gebo KA, et al. Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000-2005. Aids 2011; 25:717-720.
90. Thammavong C, Paboriboune P, Bouchard B, Harimanana A, et al. Bleach treatment of sputum samples aids pulmonary tuberculosis screening among HIV-infected patients in Laos. Int J Tuberc Lung Dis 2011; 15:1353-1358.
91. Torok ME, Nguyen TBY, Tran THC, Nguyen THM, et al. Timing of initiation of Antiretroviral Therapy in Human Immunodeficiency Virus (HIV)-Associated Tuberculous Meningitis. Clin Infect Dis 2011; 52:1374-1383.
92. von Reyn CF, Kimambo S, Mtei L, Arbeit RD, et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 2011; 15:1087-1092.
93. Walley J, Kunutsor S, Evans M, Thoulass J, et al. Validation in Uganda of the New WHO Diagnostic Algorithm for Smear-Negative Pulmonary Tuberculosis in HIV Prevalent Settings. Jaids 2011; 57:E93-E100.
94. Yin Z, Rice BD, Waight P, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS 2012; 26:87-94. [15]
95. Zhang Y, Yu L, Tang ZR, Huang SB, et al. Diagnosis of pulmonary tuberculosis among asymptomatic HIV+ patients in Guangxi, China. Chin Med J 2010; 123:3400-3405.
96. Zhang YZ, Li HJ, Cheng JL,Wu H, et al. Computed tomographic demonstrations of HIV seropositive pulmonary tuberculosis and their relationship with CD4(+) T-lymphocyte count. Chin Med J 2011; 124:693-698.